Want to see SPRB full AI Analyst Report?
Spruce Biosciences (SPRB) Stock Statistics & Valuation Metrics
Total Valuation
Spruce Biosciences has a market cap or net worth of $133.33M. The enterprise value is $42.66M.
- Market Cap
- $133.33M
- Enterprise Value
- $42.66M
Share Statistics
Spruce Biosciences has 2,874,013 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,874,013
- Owned by Insiders
- 1.00%
- Owned by Institutions
- 16.10%
Financial Efficiency
Spruce Biosciences’s return on equity (ROE) is -0.92 and return on invested capital (ROIC) is -84.42%.
- Return on Equity (ROE)
- -0.92
- Return on Assets (ROA)
- -0.73
- Return on Invested Capital (ROIC)
- -84.42%
- Return on Capital Employed (ROCE)
- -0.85
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.77M
- Employee Count
- 22
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Spruce Biosciences is -1.14. Spruce Biosciences’s PEG ratio is -0.02.
- PE Ratio
- -1.14
- PS Ratio
- 0.00
- PB Ratio
- 1.35
- Price to FCF
- -3.12
- Price to Operating Cash Flow
- -2.65
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 0 and earned -38.97M in profits. Earnings per share was -50.83.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -36.51M
- Pretax Income
- -38.97M
- Net Income
- -38.97M
- EBITDA
- -38.85M
- Earnings Per Share (EPS)
- -50.83
Cash Flow
In the last 12 months, operating cash flow was -42.62M and capital expenditures -145,000, giving a free cash flow of -42.77M billion.
- Operating Cash Flow
- -42.62M
- Free Cash Flow
- -42.77M
- Free Cash Flow per Share
- -17.59
Dividends & Yields
Spruce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32.08%
- Earnings Yield
- -45.53%
Stock Price Statistics
- Beta
- -10.78
- 52-Week Price Change
- -56.75%
- 50-Day Moving Average
- 50.24
- 200-Day Moving Average
- 55.68
- Relative Strength Index (RSI)
- 52.07
- Average Volume (3m)
- 82.10K
Important Dates
Spruce Biosciences upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Spruce Biosciences as a current ratio of 5.17, with Debt / Equity ratio of 1.73%
- Current Ratio
- 5.17
- Quick Ratio
- 5.17
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.24
- Interest Coverage Ratio
- -405.70
Taxes
In the past 12 months, Spruce Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Spruce Biosciences EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -1.05.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.92
- EV to Free Cash Flow
- -1.05
- EV to Operating Cash Flow
- -1.05
Balance Sheet
Spruce Biosciences has $96.30M in cash and marketable securities with $7.67M in debt, giving a net cash position of $88.62M billion.
- Cash & Marketable Securities
- $96.30M
- Total Debt
- $7.67M
- Net Cash
- $88.62M
- Net Cash Per Share
- $30.84
- Tangible Book Value Per Share
- $34.44
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Spruce Biosciences is $154.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $154.60
- Price Target Upside
- 233.26% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 52.43%
Scores
- Smart Score
- 2
- AI Score
- 43